CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer
CCRT with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.
Esophageal Cancer
DRUG: Paclitaxel, Cisplatin,Surgery, CCRT
Clinical and pathological response rates, 2000~2004
Progression free survival, 2000~2004|overall survival, 2000~2004|Toxicity, 2000~2004
The purpose of this study is to find out the clinical and pathological response rates of pre-operative concurrent chemoradiotherapy (CCRT) with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.